Tag Archive for: CD3
Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxXaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- HDAC6 Inhibition Restores Docetaxel Sensitivity in Resistant Prostate Cancer Cells November 16, 2026
- Newsletter 46/2026 November 15, 2026
- Phase 2 Trial: Deruxtecan in Neuroendocrine Prostate Cancer November 13, 2026
- UPDATE: First Patient Treated With ICP-B381, a Dual-Target PSMA/STEAP1 Antibody-Drug Conjugate November 13, 2026
